SCD and metabolic dysfunction-associated steatotic liver disease: Further investigations are needed to confirm in humans the results obtained in mice with MASLD-related liver disease by aramchol, a partial inhibitor of hepatic stearoyl-CoA desaturase (SCD1) [215].